[Ip-health] Pharma Anti-Counterfeiting Conference, 30th June-2nd July, London

[robert weissman]

This statement does not appear to reflect WHO views. Below is a paper on
estimates that was released by IMPACT, the anti-counterfeiting
public-private, interagency project spearheaded by WHO. It says the 10
percent figure is "not supportable." The paper below suggests "it is
reasonable to estimate that the prevalence of  counterfeit medicines
ranges from less than 1 percent of sales in developed countries, to over
10 percent  in developing countries, depending on the geographical area."



www.who.int/medicines/services/counterfeit/impact/TheNewEstimatesCounterfei=
t.pdf

Counterfeit Medicines: an update on estimates
15 November 2006

For the past few years the public opinion and expert circles have
passively accepted the argument that  10% of medicines around the world
could be counterfeit. This number however, is not supportable,  because
this figure fails to reflect the wide range in the proportion of
counterfeits across countries and  because of the difficulties in
measurement that allow only inferences to be made about the potential
range  of proportion in different regions.

Today, our capacity to collect and analyse available information has
improved, providing a better  understanding of the situation through
initiatives such as the IMPACT, with input from WHO, OECD,  IFPMA, the
Pharmaceutical Security Institute and others. We feel that an effort to
assess the presence of  counterfeiting is fundamental, but also that the
old 10% estimate needs to be clarified.

According to the WHO, a counterfeit medicine is =E2=80=9Ca medicine, which =
is
deliberately and fraudulently  mislabelled with respect to identity
and/or source.  Counterfeiting can apply to both branded and generic
products and counterfeit products may include products with the correct
ingredients or with the wrong  ingredients, without active ingredients,
with insufficient active ingredients or with fake packaging.=E2=80=9D

Certain countries have translated this definition into their
legislation. The WHO's definition encompasses  all the different legal
definitions we have identified so far. We consider consistent with the
WHO's  definition all national legislation that translates =E2=80=9Cdeliber=
ately
and fraudulently mislabelled=E2=80=9D into =E2=80=9Cif a product  contain l=
ess than xx%
of the declared active ingredient is considered counterfeit=E2=80=9D.

We advise against using a single average figure for global proportion of
counterfeit medicines because,  besides being necessarily imprecise
(i.e. not reproducible in subsequent studies) and inaccurate (i.e. not
reflecting the actual value), a single global ratio blurs the real
picture and can mislead the public.

Instead, it is necessary to use a range when describing the relevance of
counterfeiting, along with the  development status of countries
affected.  Thus, it is reasonable to estimate that the prevalence of
counterfeit medicines ranges from less than 1 percent of sales in
developed countries, to over 10 percent  in developing countries,
depending on the geographical area. This range takes into consideration
both  regional disparities in the presence of counterfeits, and specific
global market value shares. [1]

-----

Footnote [1]: Global pharmaceutical market shares are  83% for developed
markets, and 17% for developing world. Based on  audited IMS sales data,
2005 publicly available at
http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_77478579_774=
79643,00.html


-----

Analysis shows that counterfeiting is greater in those regions where
regulatory and legal oversight is  weaker, and therefore:

-  most developed countries with effective regulatory systems and market
control (e.g. USA, EU,  Australia, Canada, Japan, New Zealand) currently
have a very low proportion, i.e. less than 1% of  market value. However,
we must keep in mind that indications point to an increase in the
prevalence of counterfeit medicines even in developed countries;

-  many developing countries of Africa, parts of Asia, and parts of
Latin America have areas where  more that 30% of the medicines on sale
can be counterfeit. Other developing markets, however,  have less than
10%; overall, a reasonable estimate is between 10% and 30%;

-  many of the former Soviet republics have a proportion of counterfeit
medicines which is above  20% of market value -this falls into the
developing country range;

-  medicines purchased over the Internet from sites that conceal their
actual physical address are  counterfeit in over 50% of cases.

Apart from the huge differences between regions, variations can also be
dramatic within countries -city  versus rural areas, city versus city-,
and can even be time sensitive =E2=80=93 sometimes counterfeits are openly =
 sold
and sometimes not.

The sources of information, of course, also underlie the complexity of
any estimation. Detailed data on  counterfeit medicines is often
difficult to obtain or to publish. How to measure a market that, by
nature, is  informal and illegal =E2=80=93and where evidence is usually
consumed?

Counterfeiters and their allies know they are committing a crime and
aggressively seek to avoid detection.  They engage in elaborate
conspiracies to disguise their activities as the masters remain in the
shadows.  They establish fictitious businesses and front companies. They
exploit weaknesses in border control  whenever governments try to
promote world commerce by reducing border inspections. They use false
documents to obtain essential active pharmaceutical ingredients, as well
as manufacturing equipment to  replicate genuine products. In sum, their
actions disguise the extent of crime and makes detection and  reporting
extremely difficult.

Currently, the sources of information available include reports from
national authorities, such as drug  regulatory and enforcement agencies,
ad hoc studies conducted on a specific geographical area or  therapeutic
category, reports from the pharmaceutical sector, reports from NGOs and
surveys.

In summary, the estimated range does not aim at providing an exact
figure but rather an indication of the  different possible levels of
prevalence around the world. Even one single case of counterfeit
medicine is  not acceptable because, in addition to putting patients at
risk and undermining the public confidence in  their medicines, it also
betrays the vulnerability of the pharmaceutical supply system and
jeopardizes the  credibility of national authorities (health and
enforcement alike).

Annex

2006 Reports

Russia: The Federal Service for Health Sphere Supervision (FSHSS)
reported that 10% of all drugs on the  Russian market were counterfeit.
However, other sources estimate that the real figure could be much
higher.

Nigeria: The National Agency for Food, Drug Administration and Control
(NAFDAC) announced that the  prevalence of counterfeit drugs has dropped
to 16% at the beginning of 2006.

Reports Before 2006

Dominican Republic: The Public Health Department reported that 50% of
the pharmacies operate illegally  and that, according to the statistics,
10% of the medicines that arrive in the country are fake. Some of the
medicines found have expired over 10 years ago.

El Salvador: INQUIFAR, the association of pharmaceutical companies in El
Salvador, has denounced the  widespread availability of counterfeit
drugs on the domestic market. According to the local drug-maker  Gamma
Laboratorios, the commercialization of counterfeit medicines currently
generates economic losses  of around $40 million per year to the
country's pharmaceutical industry.

Indonesia: The International Pharmaceutical Manufacturers Group (IPMG)
in Indonesia has estimated that  pirated drugs constitute 25% of
Indonesia=E2=80=99s $2 billion pharmaceutical market. According to IPMG=E2=
=80=99s vice
chairman, those fake drugs hit foreign pharmaceutical companies=E2=80=99 bo=
ttom
lines and pose a potential  serious public health threat.

Kenya: A random survey by the National Quality Control Laboratories
(NQCL) and the Pharmacy and  Poisons Board found the almost 30% of drugs
in Kenya are counterfeit. According to Dr. Hezekiah  Chepkwony of the
NQCL, "Some of the drugs are no more than just chalk or water being
marketed as competent pharmaceutical products." According to figures
from the Kenyan Association of Pharmaceutical  Industry, counterfeit
pharmaceutical products account for approximately $130 million annually
in sales in  the country.

Peru: Some $66 million of counterfeit and adulterated pharmaceuticals
are sold in Peru every year. In  Lima alone there are 1,800 stores
devoted to this illegal business. The General Directorate of Medicines,
  Supplies and Drugs (DIGEMID) of the Department of Health (MINSA)
seized around 460,000 adulterated  and expired medicines in 2005.

Angola: According to the head of the National Department of Intellectual
Copyright Crime of the Economic  Police, Apolinario Antonio Domingos,
approximately 70% of medicines used by the Angolan population  are
forgeries.

Colombia: According to Alberto Brave, Executive President of the
Association of Colombian  Pharmaceutical Industries (ASINFAR), it has
been estimated that of a total of an annual $1,300 million  sold in
medicines, near 5 percent (some $60 million), of the products marketed
stem from contraband,  counterfeiting or adulteration.

Lebanon: The chief of Lebanon=E2=80=99s National Health Commission (NHC), I=
smail
Sakaria, stated in July 2004  that 35% of pharmaceuticals available in
the Lebanese market are counterfeit products.

exico: During 2004, federal agents seized in Sahuayo, Michoaca=CC=81n, and =
in
Guadalajara, Jalisco,  approximately 60 tons of stolen, expired and
counterfeit pharmaceuticals. There is concern in the  pharmaceutical
industry because of the growth in sales of counterfeit and contraband
products.  Reportedly, the penetration of these illegal products is
about 10% of the pharmaceutical market.

Nigeria: The chairman of Ebonyi State Task Force on Counterfeit and Fake
Drugs, Emmanuel Inya-Agha  stated that approximately 48% of goods and
drugs imported into the country are substandard or  counterfeit.
Peru: Around 200 pharmacies operate in downtown Lima with neither
registration nor authorization issued  by the ministry of health.
According to Mr. Javier Llamoza from the municipal health department,
they sell  40% contraband pharmaceuticals and 12% adulterated or expired
supplied by clandestine laboratories.  During 2004, the ministry of
health seized ten tons of adulterated pharmaceuticals.

Philippines: The former director of the Bureau of Food and Drug (BFAD),
William Torres, was quoted in  newspapers saying, "that 30% of drug
store outlets visited by food and drug deregulation officers carry  and
sell counterfeit drugs, as of 2003."

Cambodia: A Cambodian Health Ministry survey conducted in 2002 revealed
that 13% of drugs on the  domestic market were counterfeit or
substandard, especially the anti-malaria drugs and antibiotics.

China: China=E2=80=99s Research and Development-based Pharmaceutical Associ=
ation
estimated that about 8% of  over-the-counter drugs sold in China are
counterfeit.

India: Indian pharmaceutical companies have suggested that in India=E2=80=
=99s
major cities, one in five strips of  medicines sold is a fake. They
claim a loss in revenue of between 4% and 5% annually. The industry also
  estimates that spurious drugs have grown from 10% to 20% of the total
market.

Nigeria: Nigerian health officials estimate that 70% of drugs in
circulation in the country are either fake or  adulterated.

Peru: The Association of Pharmaceutical Laboratories of Peru (ALAFARPE)
estimates that the illegal  pharmaceuticals commerce in the country
represents around $40 million. This figure includes medicines  that
enter the country as contraband, expired, counterfeit, adulterated, with
altered or missing labels and  those stolen from the warehouses of the
Ministry of Health, the armed forces, and police.


James Love wrote:
> Does anyone know who at the WHO has made this claim?
>
> * "The WHO estimates that 10% of global pharmaceutical commerce involves
> counterfeits."
>
>
> -------- Forwarded Message --------
> From: Jacob Samek - Visiongain Ltd.
> <pharma.conferences1@conferencesandreports.com>
> Reply-To: pharma.conferences1@conferencesandreports.com
> To: james.love@cptech.org
> Subject: Pharma Anti-Counterfeiting Conference, 30th June-2nd July,
> London
> Date: Thu, 5 Jun 2008 04:41:37 +0100
>
> =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
> Pharmaceutical Anti-Counterfeiting Strategies Forum 2008
> =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
> 30th June, 1st & 2nd July 2008, BSG House, London
>
> Worldwide sales of counterfeit drugs could nearly double to $75bn
> (=E2=82=AC60bn, =C2=A340bn) by 2010, according to the Center for Medicine=
 in the
> Public Interest. In some developing countries more than 50 per cent of
> the drug supply is said to be counterfeit. There needs to be greater
> discussion within the industry about how to fight this problem. That is
> why the industry has made the decision to come together, meet and
> discuss how to tackle this dangerous issue as a united body.
>
> RFID, bar coding, holograms, and colour-shifting inks are very well
> known as methods of combating pharmaceutical counterfeiting. But the
> industry is constantly in search of innovative strategies to stay ahead
> of the fraudsters. Where the industry hears about the latest techniques
> and strategies is at the Annual Pharmaceutical Anti-Counterfeiting
> Strategies Conference. Will you be attending next year? If you want to
> hear about some of the latest strategies such as transparent laser
> markings of encrypted code on single product items, or new finger print
> technologies, or the latest in surface authentication systems, then
> really you need to be there.
>
> The last five years have seen an explosive growth in counterfeit
> prescription drugs that is showing no signs of relenting. This has a
> serious impact on your profit margins and poses a direct threat by
> putting patient=E2=80=99s lives at risk. The WHO estimates that 10% of gl=
obal
> pharmaceutical commerce involves counterfeits. International crime
> syndicates are becoming more sophisticated and better organised in
> counterfeiting. Is this problem at risk of spiralling out of control?
> Many analysts believe so with counterfeiting expected to reach 20 per
> cent by the 2010. They believe that as a result, counterfeiting will
> jeopardize fundamental trust in the pharmaceutical industry. So why is
> the industry waiting for a catastrophic failure before confronting
> inherent weaknesses in the system? Many aren't and the first step they
> are taking is to meet and discuss how the industry can fight back. And
> where they are meeting is in London from the 24th - 26th January. You
> must attend.
>
> The Annual Anti-counterfeiting Strategies Forum will enable global
> regulatory bodies, pharmaceutical, security and anti-counterfeiting
> companies to come together to discuss and plan a regulatory commercial
> strategy to tackle this critical problem. So how will the industry seek
> to identify the most effective countermeasures to manage risk, minimize
> brand erosion and loss of sales? Book your place now so that you can put
> you and your company=E2=80=99s voice forward in this Annual Forum.
>
> The international conference will cover themes of:
> - Routes to enabling cross-border co-operation with international
> security organisations
> - Implementation of the latest tamper-proof and automatic drug recall
> technology
> - Enhancing supply chain security through new configurations in existing
> technology
> - Ancillary benefits of improved systems for inventory and distribution
>
>
> Speakers include:
> * Andrew Jackson, Deputy Global Head, Corporate Security, Novartis
> * Janice Kite, Project Manager Traceability in Healthcare, GS1
> * Andrew Jenner, Head of IP Crime Policy, UK Intellectual Property
> Office
> * Christopher Stothers, Associate, Intellectual Property Practice Group,
> Millbank, Tweed, Hadley and McCloy
> * Monika Derecque-Pois, Secretary General, GIRP
> * Eric Noehrenberg, Director, International Trade & Market Policy,
> International Federation of Pharmaceutical Manufacturers Associations
> * Jim Thomson, CEO, Centre for Mental Health
> * Christine H=C3=A4nle, Corporate Purchasing Ethical Manager, Celesio
> * Leam Thompson, In house Counsel, Asset Investigation & Confiscation,
> BDO Stoy Hayward
> * Heinz Kobelt, Secretary General, European Association
> Euro-Pharmaceutical Companies
>
>
> Key benefits of attending
> - Identifying the scale of the problem and the drugs most commonly
> counterfeited
> - Discover the legal issues surrounding counterfeit drugs
> - Gaining insight to the market effects of parallel trading and ways to
> regulate it
> - Enhancing detection methods of fake products and ultimately deter
> counterfeiting
> - Minimizing the harm to brand name from market recall incidents
>
> How will you benefit from attending this event?
> * Meet your peers to discuss and shape the future strategies the
> industry plans to take
> * Network with senior representatives from Global regulatory bodies as
> well as major pharmaceutical companies and hear how they plan to tackle
> the industry wide problem
> * Gain an up-to-date overview and understanding of the most vital
> concerns in the battle against counterfeiters
> * Learn how to achieve a competitive edge and mitigate risks through an
> active approach with procedures to safeguard against counterfeiting
> * Explore partnership opportunities between technology providers and
> pharmaceutical corporations to enhance security of the supply chain
>
> If you only attend one event this year make sure it is the conference
> that will guarantee your success for the next few years. Places at this
> conference are limited and are issued on a strict first come, first
> served basis. Contact me now to reserve your seat.
>
>
> ________________________________________________________________________
>
> Sponsorship and exhibition opportunities:
>
> If you would like benefit by promoting your organisation at one of our
> events then exhibiting is perfect for you.
> - Network with industry decision-makers
> - Increase and maintain brand awareness
> - Meet potential clients face to face
> - Target your marketing campaign
> - Present your latest products and ideas
>
> Places at this global forum are by invitation only. The Annual
> Pharmaceutical Anti-counterfeiting Strategies Forum is growing each year
> as members of the industry meet and benefit from the forum of open
> discussion and networking. It is by tackling the problem together that
> we hope to combat and rid the industry of the dangers of counterfeit
> drugs. I would like to extend this invitation to attend to you and would
> request that you contact us now to register your attendance. We can then
> dispatch your booking confirmation and letter of approval.
>
> ________________________________________________________________________
> Who should attend:
> - Pharmaceutical companies
> - Pharmaceutical distributors
> - Government health departments
> - Public health and regulatory bodies
> - Law enforcers =E2=80=93 police, customs agencies, investigative firms
> - Non-government healthcare organisations
> - Pharmaceutical associations
> - Converters, packaging and labelling companies
> - Authentication technology suppliers
>
> Job titles: Directors, Heads and Managers of:
> - Supply Chain and Distribution
> - Packaging and Labeling
> - Compliance
> - Security
> - Information Systems
> - Regulatory Affairs
> - R&D
> - Business Development and Marketing
> - Product Information
> - Standards
> - Patient Safety
> - Pharmaceuticals/Life Sciences Analyst or
> - Business Development
> - Marketing
> - Sales
> - Security managers
>
> ________________________________________________________________________
> Conference Agenda
>
> Pre Conference Workshop, 30th June, Monday
>
> Recent Trends in International Counterfeiting
>
>
> Will include topics such as:
> =E2=80=A2 Transit shipments after Diesel v Montex
> =E2=80=A2 Liability of carriers/freight forwarders
>
>
> Daniel Marschollek, Partner, Mayer Brown
>
>
> Day One, 1st July, Tuesday
> 08:30 Refreshments and registration
>
> 09:30 Registration and refreshments
>
> 10:00 Opening address from the chair
> - Eric Noehrenberg, Director, International Trade & Market Policy,
> International Federation of Pharmaceutical Manufacturers Associations
>
> 10:10 A global strategy to fight counterfeiting
> =E2=80=A2 A safe and secure supply chain
> =E2=80=A2 Authentication and traceability
> =E2=80=A2 Activities of regulatory bodies and industry worldwide
> =E2=80=A2 Global standards =E2=80=93 how do they help fighting counterfei=
ting?
>
> Janice Kite, Project Manager Traceability in Healthcare, GS1
>
> 10:50 Technological and non-technological measures
> - How can we protect patients?
> =E2=80=A2 Product coding and identifications as pre-requisite for trackin=
g and
> tracing
> =E2=80=A2 Bar codes versus RFID
> =E2=80=A2 EU versus US: are the approaches different?
> =E2=80=A2 Stake holder and government initiatives
>
> - Monika Dereque-Pois, Director General, GIRP
>
> 11:30 Morning refreshments
>
> 11:50 The costs of counterfeit drugs
> =E2=80=A2 The burden on the health care system
> =E2=80=A2 Financial damage due to loss of sales and a reduced return on R=
&D
> investments
> =E2=80=A2 The cost of a damaged brand
>
> - Paul Forster-Jones, Managing Director, Cordia Healthcare, Board
> Member, UniChem
>
> 12:30 Stake holder and government initiatives combating counterfeits of
> medicinal products
> =E2=80=A2 The size of the problem
> =E2=80=A2 The technological approach
> =E2=80=A2 The logistical approach
> =E2=80=A2 Global asset tracing: identification of conduct & property
>
> - Tassilo Korab, Executive Director, Health Compliance Packaging Council
>
> 13:10 Networking lunch
>
> 14:30 The changes in European policy
> =E2=80=A2 Protecting IP rights
> =E2=80=A2 Is the European Union finally combating counterfeiters?
> =E2=80=A2 What will be the end result?
>
> 15:10 The UK national IP crime strategy
> =E2=80=A2 The difference between industry sectors and IP crime
> =E2=80=A2 How pursing IP infringements can deter pharmaceutical counterfe=
iting
>
> - Andrew Jenner, Head of IP Crime Policy, UK Intellectual Property
> Office
>
> 15:50 Afternoon refreshments
>
> 16:10 Closing the Security Loop: Extending E-Pedigree From Package to
> Patient
> =E2=80=A2 Counterfeiting of medications continues to escalate and is esti=
mated
> to
> reach $75 billion by 2010
> =E2=80=A2 Most Brand Protection and E-Pedigree solutions focus on ON-Pack=
age
> solutions such as RFID and 2-D bar coding
> =E2=80=A2 On-Package solutions are deemed effective but are lost once pro=
duct is
> repackaged or if the product is separated from its original packaging, a
> common occurrence in today=E2=80=99s world
> =E2=80=A2 To close the loop on product security, On-Dosage technologies t=
hat
> complement
> On-Package solutions should be employed to extend protection to the
> patient
> =E2=80=A2 Combined with a pro-active product sampling program at the reta=
il
> level, On-
> Dosage technologies can provide an =E2=80=9CEarly Warning=E2=80=9D system=
 for
> counterfeits
> and illegal diversion, allowing Pharmaceutical Manufacturers to strike
> back at
> those who steal their profits at the expense of patient=E2=80=99s well-be=
ing and
> safety
>
> - Dean Hart, Executive Vice President Comersial Operations, Nanoink
>
> 16:30 Panel discussion: Fighting the fakes =E2=80=93 To choose a combat s=
trategy
> =E2=80=A2 Should we focus on technology, legislation or a logistic approa=
ch?
> =E2=80=A2 Will tracking and tracing keep the supply chain safe?
> =E2=80=A2 Are the various efforts to combat counterfeiters coordinated en=
ough?
>
> 17:10 Closing remarks from the chair
>
> 17:15 Networking drinks
> Take your discussions further and build new relationships in a relaxed
> and informal setting
>
> Day Two, 2nd July, Wednesday
> 09:30 Registration and refreshments
>
> 10:00 Opening address from the chair
>
> Eric Noehrenberg, Director, International Trade & Market Policy,
> International Federation of Pharmaceutical Manufacturers Associations
>
> 10:10 Defending brands & pursuing offenders: The identification,
> pursuit, management & recovery of the proceeds of counterfeiting
> =E2=80=A2 Deterrents & disruption
> =E2=80=A2 Exploration of existing legislative provision to recover the pr=
oceeds
> of counterfeiting
> =E2=80=A2 Alternative civil remedies
> =E2=80=A2 Global asset tracing: identification of conduct & property
>
> - Leam Thompson, In house Counsel, Asset Investigation & Confiscation,
> BDO Stoy Hayward
>
> 10:50 Presentation to be announced
>
> - Cindy M=C3=BCller, President, Bilcare Europe
>
> 11:30 Morning refreshments
>
> 11:50 Anti-Counterfeiting technologies in the pharmaceutical industry =E2=
=80=93
> How to be effective
> =E2=80=A2 Understanding the pharmaceutical protection requirements
> =E2=80=A2 The multi-layer approach
> =E2=80=A2 Technologies, applications and success stories
> =E2=80=A2 Tracing, e-pedigree and online-authentication
> =E2=80=A2 Pre-requisites of a successful brand protection campaign
>
> - Thomas Voelcker, Director Marketing and Sales, Schreiner ProSecure
>
> 12:30 Supply chain security =E2=80=93 the logistic view
> =E2=80=A2 Are anti-counterfeiting strategies interfering with the logisti=
cs of
> the
> supply chain?
> =E2=80=A2 Examining the impact of different strategies on the supply chai=
n
> =E2=80=A2 Technology and logistics =E2=80=93 how can you use anti-counter=
feiting to aid
> logistics
>
> - Mark Harvey, Head of Security, NYK Logistics
>
> 13:10 Networking lunch
>
> 14:30 Counterfeit drugs on the internet
> =E2=80=A2 The relevance of consumer education as a part of the strategy t=
o fight
> counterfeit drugs
> =E2=80=A2 Advertising on the internet
> =E2=80=A2 Monitor internet pharmacies arranging supply chains against
> counterfeits and diversion through on-line purchases
>
> - Andrew Jackson, Deputy Global Head, Corporate Security, Novartis
>
> 15:10 The reality of internet pharmacies
> =E2=80=A2 Presenting a study of the quality of drugs bought of the intern=
et
> =E2=80=A2 Buying medicine over the internet; where does the money go?
>
> - Jim Thomson, CEO, Centre for Mental Health
>
> 15:50 Afternoon refreshments
>
> 16:10 Parallel trade and counterfeit pharmaceuticals
> =E2=80=A2 The current framework for parallel trade and repackaging of
> pharmaceuticals
> =E2=80=A2 Discovery of counterfeit pharmaceuticals in the parallel supply=
 chain
> =E2=80=A2 Actual and proposed changes to the distribution and parallel tr=
ade
> framework
>
> - Christopher Stothers, Associate, Intellectual Property Practice Group,
> Milbank, Tweed, Hadley and McCloy
>
> 16:50 The contribution of parallel trade distribution to a safe supply
> chain
> =E2=80=A2 While legal in the EU/EEA area, PT is often perceived by manufa=
cturers
> (although not by regulators) as a weakening of the distribution chain
> =E2=80=A2 The EAEPC argues that its members provide identical medicines a=
t lower
> cost than manufacturers=E2=80=99 prices to patients and final payers. Mem=
bers
> share with manufacturers the objective of fighting against counterfeits
> and raising the barriers to keep these out of the legitimate supply
> chain
> =E2=80=A2 This presentation looks at the regulatory environment for paral=
lel
> distribution and looks at the rigorously controlled business practices
> of re-packaging/re-labelling, and will demonstrate the safety profile of
> the industry. The presentation will address ways to improve the supply
> chain without jeopardizing the freedom of movement of pharmaceutical
> goods across Europe.
>
> - Heinz Kobelt, Secretary General, European Association
> Euro-Pharmaceutical Companies
>
> 17:30 Chair=E2=80=99s closing remarks
>
> ________________________________________________________________________
> List of upcoming events
>
> You may be also interested in attending other events Visiongain
> organises. Below you can find list of these events.
> If you would like to receive more information, do not hesitate
> contacting me.
>
> 3rd Annual Pharmacovigilance
> 11th - 13th June 2008, London, UK
>
> Dissolution Testing, Bioequivalence and Bioavailability Strategies
> 26th - 27th June 2008, London, UK
>
> In Vitro-in Vivo Correlation (IVIVC) Training Course
> 22nd July, London, UK
>
> Lyophilisation for Pharmaceuticals 2008
> 3rd - 5th September, London, UK
>
> 2nd Annual Optimising Stability Testing
> 17th - 19th September, London, UK
>
> Obesity Drug Development Colloquium
> 24th - 26th September 2008, London, UK
>
>
> ________________________________________________________________________
>
> - PRICING -
> - 3 day Conference ticket (inc. pre-conference workshop) - available for
> only GBP =C2=A3999 (NORMAL PRICE =C2=A31699)
> - 2 day Conference ticket - available for only GBP =C2=A3799 (NORMAL PRIC=
E
> =C2=A31299)
> - Pre-conference workshop only - GBP =C2=A3599
>
> If you would like to send more than 1 person then take advantage of the
> 3 for 2 offer. Send 3 people but only pay for 2
>
> Excellent networking opportunities.
>
> - ORDERING -
> Ordering is simple! All you need to book your place is contact Jacob
> today. You can either email me at
> pharma.conferences1@conferencesandreports.comor call on TEL: +44 (0)207
> 549 9971.
>
> Kind regards,
>
> Jacob Samek
> Visiongain Ltd.
> 4th Floor,
> BSG House,
> 226-236 City Road,
> London
> EC1V 2QY
> United Kingdom
>
>
> ________________________________________________________________________
>
>
>
> _______________________________________________
> Ip-health mailing list
> Ip-health@lists.essential.org
> http://lists.essential.org/mailman/listinfo/ip-health
>